NCT02565173 - Study of Trabodenoson in Adults With Ocular Hypertension or Primary Open-angle Glaucoma | Biotech Hunter

Enrollment

303

Participants

Timeline

Start Date

September 30, 2015

Primary Completion Date

November 30, 2016

Study Completion Date

November 30, 2016

Conditions

Primary Open-Angle Glaucoma (POAG)Ocular Hypertension (OHT)

Interventions

DRUG

trabodenoson 4.5% BID

Trabodenoson 4.5% administered twice per day in both eyes for 12 weeks.

DRUG

trabodenoson 6.0% QD

Trabodenoson 6.0% administered once per day in the morning in both eyes followed by matching placebo administered once per day in the evening in both eyes for 12 weeks.

DRUG

trabodenoson 3.0% QD

Trabodenoson 3.0% administered once per day in the morning in both eyes followed by matching placebo administered once per day in the evening in both eyes for 12 weeks.

DRUG

timolol 0.5% BID

Timolol 0.5% administered twice per day in both eyes for 12 weeks.

DRUG

placebo BID

Placebo administered twice per day in both eyes for 12 weeks.

Trial Locations (1)

02421

Inotek Pharmaceuticals Corporation, Lexington